CN116133680A - 抗非洲猪瘟病毒感染的疫苗 - Google Patents

抗非洲猪瘟病毒感染的疫苗 Download PDF

Info

Publication number
CN116133680A
CN116133680A CN202180019982.7A CN202180019982A CN116133680A CN 116133680 A CN116133680 A CN 116133680A CN 202180019982 A CN202180019982 A CN 202180019982A CN 116133680 A CN116133680 A CN 116133680A
Authority
CN
China
Prior art keywords
ep402r
protein
seq
amino acid
asf virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019982.7A
Other languages
English (en)
Chinese (zh)
Inventor
L.迪克森
A.雷斯
A.帕塔克里什南
S.戴维斯
Y.J.吕
池水信二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
The Pirbright Institute
Kumamoto University
Original Assignee
University of Oxford
The Pirbright Institute
Kumamoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by University of Oxford, The Pirbright Institute, Kumamoto University filed Critical University of Oxford
Publication of CN116133680A publication Critical patent/CN116133680A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180019982.7A 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗 Pending CN116133680A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GB2003289.2 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2005878.0 2020-04-22
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2005880.6 2020-04-22
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
GB2013541.4 2020-08-28
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
CN116133680A true CN116133680A (zh) 2023-05-16

Family

ID=74870840

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180019982.7A Pending CN116133680A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019234.9A Pending CN115397463A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019437.8A Pending CN115605223A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202180019234.9A Pending CN115397463A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗
CN202180019437.8A Pending CN115605223A (zh) 2020-03-06 2021-03-05 抗非洲猪瘟病毒感染的疫苗

Country Status (13)

Country Link
US (3) US20240293525A1 (cg-RX-API-DMAC7.html)
EP (3) EP4114454A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516713A (cg-RX-API-DMAC7.html)
KR (2) KR20230013017A (cg-RX-API-DMAC7.html)
CN (3) CN116133680A (cg-RX-API-DMAC7.html)
AU (2) AU2021231402A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016893A8 (cg-RX-API-DMAC7.html)
CA (2) CA3170058A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002412A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014152A2 (cg-RX-API-DMAC7.html)
MX (2) MX2022010372A (cg-RX-API-DMAC7.html)
PH (2) PH12022552084A1 (cg-RX-API-DMAC7.html)
WO (3) WO2021176234A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224669A (zh) * 2023-07-31 2023-12-15 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
EP4565269A2 (en) * 2022-08-04 2025-06-11 Malcolm, Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
CN120936878A (zh) * 2022-11-22 2025-11-11 马德里黄金标准诊断公司 用于区分感染asfv与asfv疫苗接种的动物的方法
CN120897756A (zh) * 2022-11-22 2025-11-04 英特维特国际股份有限公司 减毒非洲猪瘟病毒及其在疫苗组合物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224669A (zh) * 2023-07-31 2023-12-15 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Also Published As

Publication number Publication date
US20230117978A1 (en) 2023-04-20
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
CL2022002412A1 (es) 2023-03-03
CN115397463A (zh) 2022-11-25
CN115605223A (zh) 2023-01-13
CL2022002416A1 (es) 2023-03-03
WO2021176235A1 (en) 2021-09-10
JP2023516709A (ja) 2023-04-20
US20230124042A1 (en) 2023-04-20
EP4114453A1 (en) 2023-01-11
CO2022014256A2 (es) 2022-12-30
KR20230013016A (ko) 2023-01-26
WO2021176236A1 (en) 2021-09-10
MX2022010372A (es) 2023-01-19
JP2023516713A (ja) 2023-04-20
EP4114455A1 (en) 2023-01-11
PH12022552084A1 (en) 2024-02-26
MX2022010373A (es) 2023-01-19
BR112022016893A8 (pt) 2023-02-28
KR20230013017A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
AU2021231402A1 (en) 2022-11-03
AU2021229654A1 (en) 2022-11-03
US20240293525A1 (en) 2024-09-05
BR112022016893A2 (pt) 2023-01-24
CO2022014152A2 (es) 2023-02-16
PH12022552086A1 (en) 2023-11-20
CA3170058A1 (en) 2021-09-10
EP4114454A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US20240293525A1 (en) Vaccine against african swine fever virus infection
JP7591043B2 (ja) 遺伝子i177lの欠失に基づく新規なアフリカ豚熱弱毒化生ワクチンの開発
RS65124B1 (sr) Racionalno razvijeni soj oslabljenog virusa afričke svinjske groznice koji štiti od izazivanja parentalnog izolata virusa georgia 2007
EP3157550A1 (en) Attenuated african swine fever virus vaccine
CN106456741B (zh) 包含e2蛋白tav表位中的取代的重组经典猪瘟病毒(csfv)
CN114015660B (zh) 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN102459578A (zh) 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法
CN115717129A (zh) 一种非洲猪瘟病毒基因缺失的重组减毒株及其制备方法与应用
Guo et al. Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens
JP7387623B2 (ja) 標的タンパク質を安定して発現できる組換えウイルス
TWI797603B (zh) 免疫組合物
Yao et al. The construction and immunogenicity analyses of a recombinant pseudorabies virus with porcine circovirus type 3 capsid protein co-expression
JP7703030B2 (ja) 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
CN111925994B (zh) 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用
RU2725952C1 (ru) Вакцина против hev
Li et al. Development and characterization of Rift Valley fever virus-like particles
CN121752290A (zh) Dev作载体的禽流感h9疫苗
KR20230084078A (ko) 제3 유전자형 e형 간염 바이러스 캡시드 단백질의 면역원성 단편 또는 이의 바이러스-유사 입자를 포함하는 e 형 간염의 예방 또는 치료용 백신 조성물
CN117916362A (zh) 基于a137r基因缺失的新型非洲猪瘟减毒活疫苗的开发
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
WO2020115329A1 (en) A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
WO2025049941A1 (en) Attenuated vaccinia virus vaccines for monkeypox
TWI399382B (zh) 突變型雞傳染性華氏囊病病毒vp2蛋白及其用途
Egyed et al. Genomic and pathogenic studies on a glycoprotein E variant field isolate of bovine herpesvirus 1
KR20250179193A (ko) 아프리카 돼지 열병 바이러스 백신용 다중 에피토프 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination